TOP TEN perturbations for 39116_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39116_at
Selected probe(set): 208716_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39116_at (208716_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) / endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):5.802641Number of Samples:3 / 2
| Experimental | endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary adenocarcinoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.620308Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.519865Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
DSG2 depletion study 1 (siRNA) / control siRNA treated microvascular endothelial cell sample
Relative Expression (log2-ratio):2.391407Number of Samples:3 / 3
| Experimental | DSG2 depletion study 1 (siRNA) |
| Microvascular endothelial cells (MVECs) treated with siRNA targeting desmoglein-2 (DSG2). siRNA was obtained from Dharmacon and incorporated into cationic liposomes using DharmaFECT transfection reagent. After 24-48 hours expression analysis was performed. Primary cells were isolated from skin biopsy of patients undergoing hand surgery. At the time of cell isolation patients were not receiving steroids, cyclophosphamide, D-penicillamine, relaxin, or other disease-modifying drugs. 10 days before biopsy calcium channel blockers were also stopped. In contrast, proton-pump inhibitors and cisapride were allowed. | |
| Control | control siRNA treated microvascular endothelial cell sample |
| Microvascular endothelial cells (MVECs) treated with not-targeting siRNA as a negative control. siRNA was obtained from Dharmacon and incorporated into cationic liposomes using DharmaFECT transfection reagent. After 24-48 hours expression analysis was performed. Primary cells were isolated from skin biopsy of patients undergoing hand surgery. At the time of cell isolation patients were not receiving steroids, cyclophosphamide, D-penicillamine, relaxin, or other disease-modifying drugs. 10 days before biopsy calcium channel blockers were also stopped. In contrast, proton-pump inhibitors and cisapride were allowed. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.1293898Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.0492516Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (TEL-AML1)
Relative Expression (log2-ratio):2.0211143Number of Samples:2 / 21
| Experimental | precursor-B-ALL study 2 (E2A-PBX1) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
| Control | precursor-B-ALL study 2 (TEL-AML1) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG). |
Langerhans cell histiocytosis study 4 / normal tonsillar T-lymphocyte sample
Relative Expression (log2-ratio):-1.959629Number of Samples:7 / 4
| Experimental | Langerhans cell histiocytosis study 4 |
| CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease). | |
| Control | normal tonsillar T-lymphocyte sample |
| Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-1.8074799Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):1.7616196Number of Samples:2 / 4
| Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
| Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |